13G Filing: Sabby Capital and Sellas Life Sciences Group Inc. (SLS)

Page 4 of 9 – SEC Filing

12.
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

OO
CUSIP No.
81642T1001.
NAME OF REPORTING PERSONSHal Mintz2.
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

(a) [_]

(b) [X]

3.
SEC USE ONLY4.
CITIZENSHIP OR PLACE OF ORGANIZATIONUSANUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

5.
SOLE VOTING POWER06.
SHARED VOTING POWER 112,7947.
SOLE DISPOSITIVE POWER08.
SHARED DISPOSITIVE POWER 112,7949.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 112,79410.
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES (SEE INSTRUCTIONS)

[_]11.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)7.4012.
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

IN?

CUSIP No.
81642T100

Item 1.
(a).
Name of Issuer:SELLAS Life Sciences Group, Inc

(b).
Address of issuer’s principal executive offices:310 N State Street Suite 208
Lake Oswego OR 97034

Item 2.
(a).
Name of person filing:Sabby Healthcare Master Fund, Ltd.
Sabby Volatility Warrant Master Fund, Ltd.
Sabby Management, LLC
Hal Mintz

Follow Sellas Life Sciences Group Inc. (NASDAQ:SLS)